TRIPALMITIN is a lipid of Glycerolipids (GL) class. Tripalmitin is associated with abnormalities such as Atherosclerosis, Hypoalphalipoproteinemias, Cystic Fibrosis, PARKINSON DISEASE, LATE-ONSET and Obesity. The involved functions are known as 5-(carboxyamino)imidazole ribonucleotide mutase activity, Certification, phosphatidylcholine-sterol O-acyltransferase activity, Regulation and Uptake. Tripalmitin often locates in Blood, Hepatic, Body tissue, Gastric mucosa and Biopsy sample. The associated genes with TRIPALMITIN are PON1 gene, very high density lipoproteins, THEMIS gene, HEPATIC PROTEIN and chylomicron remnant. The related lipids are Fatty Acids, Total cholesterol, Nonesterified Fatty Acids, Palmitates and tristearin.
To understand associated biological information of TRIPALMITIN, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
TRIPALMITIN is suspected in Atherosclerosis, Fatty Liver, Cystic Fibrosis, Hypoalphalipoproteinemias, PARKINSON DISEASE, LATE-ONSET, Obesity and other diseases in descending order of the highest number of associated sentences.
| Disease | Cross reference | Weighted score | Related literature |
|---|
We collected disease MeSH terms mapped to the references associated with TRIPALMITIN
| MeSH term | MeSH ID | Detail |
|---|---|---|
| Leishmaniasis, Visceral | D007898 | 13 associated lipids |
| Respiratory Distress Syndrome, Newborn | D012127 | 5 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Malabsorption Syndromes | D008286 | 16 associated lipids |
| HIV-Associated Lipodystrophy Syndrome | D039682 | 3 associated lipids |
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
| Location | Cross reference | Weighted score | Related literatures |
|---|
| Function | Cross reference | Weighted score | Related literatures |
|---|
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
| Gene | Cross reference | Weighted score | Related literatures |
|---|
There are no associated biomedical information in the current reference collection.
| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Appel B et al. | Lipidic implants for controlled release of bioactive insulin: effects on cartilage engineered in vitro. | 2006 | Int J Pharm | pmid:16569486 |
| Elkharraz K et al. | Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. | 2006 | Int J Pharm | pmid:16490330 |
| Koennings S et al. | In vitro investigation of lipid implants as a controlled release system for interleukin-18. | 2006 | Int J Pharm | pmid:16513302 |
| Guse C et al. | Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids. | 2006 | Int J Pharm | pmid:16517106 |
| Tsai MJ et al. | Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. | 2012 | Int J Pharm | pmid:22193056 |
| Garcia-Fuentes M et al. | New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. | 2005 | Int J Pharm | pmid:15885464 |
| Illing A and Unruh T | Investigation on the flow behavior of dispersions of solid triglyceride nanoparticles. | 2004 | Int J Pharm | pmid:15454303 |
| Lopes DG et al. | Microphase separation in solid lipid dosage forms as the cause of drug release instability. | 2017 | Int J Pharm | pmid:28007547 |
| Becker K et al. | Advanced stable lipid-based formulations for a patient-centric product design. | 2016 | Int J Pharm | pmid:26621689 |
| Bondì ML et al. | Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells. | 2015 | Int J Pharm | pmid:26211902 |
| Witzleb R et al. | Dissolution of solid lipid extrudates in biorelevant media. | 2012 | Int J Pharm | pmid:22044538 |
| Kumar VV et al. | Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. | 2007 | Int J Pharm | pmid:17161566 |
| Fadda P et al. | Solid lipid nanoparticle preparation by a warm microemulsion based process: influence of microemulsion microstructure. | 2013 | Int J Pharm | pmid:23422277 |
| Reithmeier H et al. | Development and characterization of lipid microparticles as a drug carrier for somatostatin. | 2001 | Int J Pharm | pmid:11337157 |
| Olbrich C et al. | Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)--effect of surfactants, storage time and crystallinity. | 2002 | Int J Pharm | pmid:11955810 |
| Ahlin P et al. | Influence of spin probe structure on its distribution in SLN dispersions. | 2000 | Int J Pharm | pmid:10699727 |
| Schwendner SW et al. | Potential organ or tumor imaging agents. 32. A triglyceride ester of p-iodophenyl pentadecanoic acid as a potential hepatic imaging agent. | 1992 | Int J Rad Appl Instrum B | pmid:1522018 |
| Jawahar N et al. | Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. | 2018 | Int. J. Biol. Macromol. | pmid:29402457 |
| Schneider M et al. | A new ultrasound contrast agent based on biodegradable polymeric microballoons. | 1991 | Invest Radiol | pmid:1808125 |
| Potta SG et al. | Development of solid lipid nanoparticles for enhanced solubility of poorly soluble drugs. | 2010 | J Biomed Nanotechnol | pmid:21361127 |